17 June 2013
Optibrium, a developer of software for drug discovery, has released version 5.4 of its StarDrop software platform.
The company says the new release offers enhanced features to guide the design of novel, safe and efficacious drugs by providing access to world-leading technologies for toxicity prediction and bioisosteric transformations. These new optional modules further extend StarDrops capabilities to intuitively target high-quality compounds in drug discovery, reducing the time and cost to deliver drug candidates with an improved chance of success.
The new Derek Nexus module for StarDrop, developed in collaboration with Lhasa Limited, provides knowledge-based predictions of the likelihood of a compound causing toxicity in more than 40 endpoints, including mutagenicity, carcinogenicity and hepatotoxicity.
Integrated with StarDrops Glowing Molecule visualisation, this new module guides the redesign of compounds to reduce the potential for toxicity, the company says. An easy-to-use reporting feature facilitates collaboration between chemists and expert toxicologists to interpret the results, enabling effective, timely decision-making regarding the prioritisation of chemistries early in the drug discovery process.